SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics priced a $600M underwritten offering of 18.2M common…

Tango Therapeutics, Inc. · PRESS-RELEASE filed Jun 9, 2026 at 22:49 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jun 9, 2026 at 22:49 ET

Tango Therapeutics priced a $600M underwritten offering of 18.2M common shares and pre-funded warrants at $30/share, with an underwriter option for an additional 3M shares. For a clinical-stage biotech with a $4.5B market cap, this represents ~13.3% dilution of current shares outstanding (excluding the option), providing substantial cash runway but signaling significant near-term dilution.

  • Priced 18,166,667 common shares at $30.00 per share
  • Priced pre-funded warrants for 1,833,395 shares at $29.999 each
  • Gross proceeds expected to be approximately $600 million
  • Underwriters granted 30-day option to purchase up to 3,000,009 additional shares

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access